B[ACKGROUND]{.smallcaps} {#sec1-1}
========================

β-endorphin is recognized as one of the most significant endogenous neuropeptides.\[[@ref1]\] It is present abundantly in the hypothalamus and pituitary gland and released when the body encounters any sort of stress or pain.\[[@ref2][@ref3][@ref4]\] There are two functionally different systems for the release of β-endorphins, one for the peripheral effects via the systemic circulation and one directed at the central nervous system (CNS).\[[@ref5]\] Numerous immunocytochemical as well as *in situ* hybridization studies have confirmed the existence of a main population of β-endorphins-immunoreactive neurons, described as pro-opiomelanocortin (POMC) neurons in the mediobasal hypothalamic region, most of them located in the arcuate hypothalamic nucleus.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] In addition to the POMC neurons in the hypothalamus, the pituitary contains large numbers of POMC-producing cells located in the intermediate as well as in the anterior lobes.\[[@ref13]\] β-endorphins produced in the pituitary is for release into the peripheral systemic circulation, whereas that produced in the hypothalamic POMC neurons is for release inside the CNS.\[[@ref5]\] Thus, β-endorphin is found in both plasma and cerebrospinal fluid (CSF).

Previous studies have suggested that an intact blood--brain barrier (BBB) prevents the free exchange of β-endorphin between plasma and CSF,\[[@ref14][@ref15]\] thus CSF levels of β-endorphins were believed not to be a reflection of the peripheral levels, but to be controlled and regulated by separate inputs and by specific mechanisms that have separate functions from the pituitary release mechanisms involved in the plasma levels.\[[@ref5]\] However, it was later found that peripheral β-endorphins may be able to reach the CNS from the periphery via the circumventricular organs (which lack the BBB) as well as the choroid plexus.\[[@ref16][@ref17]\] Conversely, CSF peptides such as β-endorphins can gain access from brain to blood at the brain capillaries through the transporter mechanism by P-glycoprotein.\[[@ref18][@ref19][@ref20]\]

It is also known that endorphin levels rise during stress\[[@ref2][@ref3][@ref4]\] and inflammation.\[[@ref4][@ref21][@ref22][@ref23]\] Cytokines such as tumor necrosis factor-α have been postulated to contribute to the production of β-endorphin in inflamed tissues.\[[@ref24]\] Many studies have reported a lack of correlation between the plasma and CSF β-endorphin levels in different clinical states,\[[@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32]\] whereas a few others reported positive correlation.\[[@ref5][@ref33][@ref34]\] However, no previous report is available on the relationship between β-endorphin levels in the CSF and plasma of children with cerebral malaria (CM). This article is a report on a part of a study on β-endorphin in children with CM carried out at Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Participants {#sec2-1}
------------

This was a cross-sectional study involving 40 children, aged between 6 months and 14 years, admitted with a diagnosis of CM. The diagnosis of CM was based on the World Health Organization (WHO)\[[@ref35]\] criteria as follows: unarousable coma (Blantyre Coma Score ≤2) for more than 30min, presence of asexual forms of Plasmodium falciparum parasitemia in peripheral blood film, and exclusion of other common causes of loss of consciousness (such as meningitis and head trauma).

Exclusion criteria include history suggestive of underlying chronic medical conditions such as chronic kidney disease, sickle cell anemia, cerebral palsy, or seizure disorder. The participants were recruited consecutively into the study following admission to the children emergency ward of the OAUTHC.

Ethical approval for the study was obtained from the OAUTHC Ethics and Research Committee. Informed consent was obtained from the parents or guardian of each participant.

The bio-data collected included the age, sex, and anthropometric data of the participants as well as the socioeconomic status of the parents or guardians. Social class was determined using the method described by Oyedeji,\[[@ref36]\] which makes use of the occupation and highest education of both the parents.

Weight (in kilograms) was measured to the nearest 0.05kg using the Waymaster weighing scale (made in England) for children weighing below 13kg. Weight for older children was measured to the nearest 0.5kg using RGZ-160 weighing scale by Leaidal Medical, United Kingdom. Length was measured to the nearest 0.1 cm using an infantometer for infants or with an inelastic tape measure on a rigid board with head and feet plates for older children. We measured length instead of height in the older patients because they were unconscious. The length was measured after ensuring that the child was lying flat with the occiput, buttocks, and heel touching the board and knees gently pressed down to straighten out the legs.

Nutritional status was assessed from the obtained anthropometric measurements using the National Centre for Health Statistics/WHO reference growth charts for weight-for-age, weight-for-height, and height-for-age, and body mass index (BMI). Values less than two standard deviations (SDs) below the mean were taken as underweight (weight-for-age criterion), wasting (weight-for-height criterion), and stunting (height-for-age criterion). The Wellcome classification was also used to classify the nutritional state of the children aged 5 years and below.\[[@ref37]\] For children older than 5 years, BMI was used. The 5th to 84th percentile range is normal weight, below 5th percentile is underweight, 85th to 95th percentile is at risk for overweight, above 95th percentile is overweight, and below 5th percentile is underweight.\[[@ref38]\]

Investigation {#sec2-2}
-------------

Blood sample was collected from the participants at admission using a 21G needle after sterilizing the site thoroughly. This was used for the measurement of β-endorphin levels. Lumbar puncture was also carried out as a routine procedure to exclude meningitis. One milliliter of the CSF was put in a eppendorf tubes for the determination of β-endorphin level. The blood sample was collected in ethylenediaminetetraacetic acid bottles and centrifuged at 1500 revolutions per minute for 15min. The plasma was separated and transported with CSF samples in ice packs until analyzed and then stored together with the CSF sample at --80°C before analysis.

CSF and plasma β-endorphin levels were determined at the research laboratory located at the Department of Biochemistry, Obafemi Awolowo University (OAU), Ile-Ife, Nigeria, using the enzyme-linked immunosorbent assay (ELISA) kit E90806Hu obtained from USCN Life Sciences, China. The kit uses a competitive enzyme inhibition immunoassay technique for the *in vitro* quantitative measurement of β-endorphin in human serum, plasma, CSF, and other biological fluids with the inter- and intra-assay coefficients of variation of \<12% for serum and \<10% for CSF. A monoclonal antibody specific for human β-endorphin was pre-coated onto a microplate. A competitive inhibition reaction was launched between biotin-labeled human β-endorphin and unlabeled human β-endorphin (standards or samples) with the pre-coated antibody specific for human β-endorphin. After incubation, the unbound conjugate was washed off. Next, avidin conjugated to horseradish peroxidase (HRP) was added to each microplate well and incubated. The amount of bound HRP conjugate was proportional to the intensity of color developed, whereas both were inversely proportional to the concentration of β-endorphin in the sample. An average of the duplicate readings for each standard, control, and samples was taken. Thereafter, standard curve was constructed on a graph paper by plotting the log of concentration of β-endorphin against the absorbance. The concentration of β-endorphin of the CSF and plasma samples was determined by drawing a line of best fit through the points of intersection on the graph.

Statistical analysis {#sec2-3}
--------------------

Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software for Windows, version 16.0 (SPSS Inc., Chicago, IL). Descriptive statistics including age, gender, socioeconomic characteristics, and anthropometry of the subjects were analyzed and presented using frequency tables. Measures of central tendency were used as appropriate to present continuous variables such as the β-endorphin levels of the study population. Bivariate linear regression was used to determine the degree and direction of association between plasma and CSF β-endorphin levels. This was carried out by determining the correlation coefficient (r), coefficient of determination (*R*^2^), and *P* values. The level of statistical significance was set at *P* value of less than 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Demographic characteristics

The age range of the study participants was between 8 and 84 months with a mean of 32.9 (18.6) months. Ninety percent of these participants were 5 years old or younger. The age group with the highest number of subjects was the 13--24 months age group, which accounted for 40% of all the subjects studied. The frequency of CM peaked in this age range. The age and gender distribution of the participants are shown in [Table 1](#T1){ref-type="table"}.

###### 

Age and gender distribution of the participants

  Variable              Participants *n* (%)
  --------------------- ----------------------
  Age distribution      
   6--12 months         4 (10.0)
   13--24 months        16 (40.0)
   25--36 months        10 (25.0)
   37--60 months        6 (15.0)
   \>60 months          4 (10.0)
  Gender distribution   
   Male                 25 (62.5)
   Female               15 (37.5)

*N* = number (frequency)

Social class distribution of the study participants and the relationship with β-endorphin levels {#sec2-4}
------------------------------------------------------------------------------------------------

Using the social class classification method described by Oyedeji\[[@ref36]\] (Appendix IV); it was found that none of the subjects with CM were from social class I, 4 (10.0%) were from class II, whereas 16 (40.0%) were from social class III, and 18 (45.0%) were from social class IV, respectively. Only two (5.0%) were from social class V. Therefore, 20 (50.0%) of the children with CM were from the lower social classes (IV and V), whereas the remaining half were from higher social classes (II and III). However, no significant relationship was found between the social classes of the subjects and the β-endorphin levels in either their CSF (F = 0.496, *P* = 0.687) or their plasma (F = 0.440, *P* = 0.726).

Correlation between plasma and CSF β-endorphin levels at admission {#sec2-5}
------------------------------------------------------------------

The mean ± SD plasma β-endorphin level for the subjects was 3.1±2.0 pmol/L (range: 1.0--10.4 pmol/L), whereas the mean CSF β-endorphin level was 1.8±0.9 pmol/L (range: 0.8--3.4 pmol/ L). [Figure 1](#F1){ref-type="fig"} shows the correlation between plasma and CSF β-endorphin levels at admission. The plasma β-endorphin levels significantly positively correlated with CSF β-endorphin (*r* = 0.568, *P* ≤ 0.001) such that for every unit rise in plasma β-endorphin, CSF β-endorphin rises by 0.252 pmol/L (confidence interval: 0.132--0.371 pmol/ L). This was carried out by determining the r, (*R*^2^), and *P* values.

![Correlation between plasma and CSF β-endorphin levels at admission](JPN-13-416-g001){#F1}

Anthropometric parameters of the participants {#sec2-6}
---------------------------------------------

The anthropometry of the subjects is shown in [Table 2](#T2){ref-type="table"}. Over 75% of the children with CM, aged 60 months and below, had normal values of weight for age (77.8%) and height for age (86.1%), whereas only 60.0% had normal weight for height z scores. Wasting was the most common type of undernutrition, whereas stunting was the least common. Using the Wellcome classification, only one child had marasmus. Three (75.0%) of the four children, older than 60 months, had normal BMI (5th--84th percentile), whereas the remaining one was at risk of overweight (85th--95th percentile).

###### 

Anthropometry of the participants

  Anthropometric parameters     No. of children   Percentage 100.0%
  ----------------------------- ----------------- -------------------
  Weight-for-age *z* score      (*n* = 36)\*      
   Normal                       28                77.8
   Underweight                  5                 13.9
   Severe underweight           3                 8.3
  Height-for-age *z* score      (*n* = 36)\*      
   Normal                       31                86.1
   Mild to moderate stunting    4                 11.1
   Stunting                     1                 2.8
  Weight-for-height *z* score   (*n* = 36)\*      
   Normal                       24                60.0
   Mild to moderate wasting     6                 15.0
   Severe wasting               6                 15.0
  Wellcome classification       (*n* = 36)\*      
   Normal                       30                83.3
   Underweight                  5                 13.9
   Marasmus                     1                 2.8
  BMI percentile                (*n* = 4)\*\*     
   Normal                       3                 75.0
   At risk of overweight        1                 25.0

\*Children aged 60 months and below, \*\*children older than 60 months

The relationships between CSF and plasma β-endorphin levels and anthropometric parameters of the participants are as shown in \[Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\], respectively. No statistically significant relationship was found between CSF or plasma β-endorphin levels and the nutritional status of the subjects (*P* \> 0.05).

###### 

Relationship between CSF β-endorphin levels and anthropometric parameters of the participants

  Anthropometric parameters             No of children *n* (%)   Mean CSF β-endorphin level   *F* value   *P* value
  ------------------------------------- ------------------------ ---------------------------- ----------- -----------
  Weight-for-age *z* score              (*n* = 36)                                                        
   Normal                               28 (77.8)                1.8 ± 0.9                    0.601       0.558
   Underweight                          5 (13.9)                 1.5 ± 1.0                                
   Severe underweight                   3 (8.3)                  1.4 ± 0.9                                
  Height-for-age *z* score              (*n* = 36)                                                        
   Normal                               31 (86.1)                1.8 ± 0.9                    0.435       0.651
   Stunting                             5 (13.9)                 1.5 ± 1.1                                
  Weight-for-height *z* score           (*n* = 36)                                                        
   Normal                               24 (60.0)                2.0 ± 0.9                    1.566       0.224
   Mild to moderate wasting             6 (15.0)                 1.3 ± 0.6                                
   Severe wasting                       6 (15.0)                 1.5 ± 1.0                                
  BMI percentile                        (*n* = 4)\*\*                                                     
   Normal (5th--85th percentile)        3 (75.0)                 1.7 ± 1.0                    -0.645      0.585
   At risk of overweight (85th--95th)   1 (25.0)                 2.5                                      

\*Children aged 60 months and below, \*\*children older than 60 months

###### 

Relationship between plasma β-endorphin levels and anthropometric parameters of the participants

  Anthropometric parameters             No. of children *n* (%)   Mean plasma β-endorphin level   *F* value   *P* value
  ------------------------------------- ------------------------- ------------------------------- ----------- -----------
  Weight-for-age *z* score              (*n* = 36)\*                                                          
   Normal                               28 (77.8)                 3.1 ± 2.2                       0.110       0.896
   Underweight                          5 (13.9)                  3.6 ± 2.3                                   
   Severe underweight                   3 (8.3)                   3.2 ± 1.4                                   
  Height-for-age *z* score              (*n* = 36)\*                                                          
   Normal                               31 (86.1)                 3.1 ± 2.1                       0.471       0.628
   Stunting                             5 (13.9)                  4.0 ± 2.4                                   
  Weight-for-height *z* score           (*n* = 36)\*                                                          
   Normal                               27 (75.0)                 3.4 ± 2.4                       0.549       0.583
   Mild to moderate wasting             6 (16.7)                  2.5 ± 1.2                                   
   Severe wasting                       3 (8.3)                   2.9 ± 1.0                                   
  BMI percentile                        (*n* = 4)\*\*                                                         
   Normal (5th--85th percentile)        3 (75.0)                  1.8 ± 1.0                       -2.190      0.160
   At risk of overweight (85th--95th)   1 (25.0)                  2.8                                         

\*Children aged 60 months and below, \*\*children older than 60 months

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The age distribution of the children with CM in this study is similar to what has been found in previous studies where the incidence of CM was found to be higher in children below 5 years.\[[@ref39][@ref40][@ref41][@ref42][@ref43][@ref44]\] The age group with the highest incidence of CM in this study (13--24 months) is also similar to previous findings.\[[@ref41][@ref42][@ref44]\] This is the period when children are most susceptible to infections, especially severe forms of malaria. The loss of passive immunity acquired from the mother, decrease in concentration of fetal hemoglobin to adult values, as well as the increased activities and exposure of these children to mosquito bites are adduced to be responsible for this susceptibility. The fact that four children in the study population were above 5 years of age suggests that CM is still found in older children, probably as a result of the rebound effect of malaria prevention methods on the immunity in older children, resulting in delayed acquisition of or reduction in previously acquired malaria immunity.\[[@ref45][@ref46][@ref47]\]

In this study, the mean plasma β-endorphin levels seen in children with CM were higher than CSF levels. It has been reported that an intact BBB prevents the free exchange of β-endorphin between plasma and CSF. However, little transport of β-endorphin between CSF and plasma may occur through circumventricular organs and P-glycoprotein. This may be contributory to the higher plasma β-endorphin levels in CM.

The finding of a positive correlation between plasma and CSF β-endorphin levels is contrary to what has been reported in many previous studies,\[[@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32]\] where no correlation was found between them. However, a few studies reported positive correlation between plasma β-endorphin and CSF β-endorphin levels.\[[@ref5][@ref33][@ref34]\] The positive correlation between plasma and CSF β-endorphin levels in this study may suggest a possible communication between the plasma and CSF in CM. This can be as a result of a disruption of the BBB, which has been reported in CM.\[[@ref48][@ref49]\] A simultaneous response from the peripheral and central systems for β-endorphin production is also possible.

The rarity of severe malnutrition observed in this study both with WHO z scores as well as with Wellcome classification is similar to the finding by Olumese *et al*.\[[@ref50]\] in Ibadan who reported only one case of marasmus among 55 children with CM studied. Researchers have different opinions on the role of undernutrition in malarial susceptibility and severity. Some have suggested that severe malaria is less likely in undernourished children compared to well-nourished ones because of the deficiency of nutrients, which the malaria parasite thrives on, in these malnourished children.\[[@ref50][@ref51]\] Some other researchers postulated that improved nutrition reduces the likelihood of severe malaria including CM because micronutrient deficiencies in undernourished children suppress their immunity against malarial parasite by impairing complement function and antibody production by thymic and splenic lymphocytes.\[[@ref50][@ref51][@ref52]\] However, no significant association is present between nutritional status of the subjects in this study and the β-endorphin levels, suggesting that nutritional status may not be contributory to the β-endorphin levels in CM. Also, no significant relationship was reported between the social classes of the subjects and the β-endorphin levels in CSF and plasma, suggesting that β-endorphin level is not affected by the socioeconomic variation of the subjects.

An objective way of ascertaining the positive correlation found between the CSF and plasma β-endorphin levels in children with CM is to carry out the serial measurements of the CSF and plasma β-endorphins. However, this may be unethical in many clinical settings. Thus, it may suffice to analyze plasma β-endorphin levels only in studies on children with CM where repeated lumbar punctures may be unethical. The findings of this study therefore suggest that in CM, CSF β-endorphin levels rise as the plasma β-endorphin levels increase, possibly as a result of a direct link between the plasma and CSF in CM because of the disruption of BBB by the inflammatory process.
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